DOCK2 and B-cell chronic lymphocytic leukemia: Notably, DOCK2 is a potent RAC1 activator in cancers, including melanoma and chronic lymphocytic leukemia [58–60], and regulates critical processes such as lymphocyte migration, T-cell differentiation, cell-cell adhesion, and bone marrow homing of immune cells [61].